0% found this document useful (0 votes)
65 views24 pages

Mindsets Matter: A New Framework For Harnessing The Placebo Effect in Modern Medicine

Download as pdf or txt
Download as pdf or txt
Download as pdf or txt
You are on page 1/ 24

CHAPTER EIGHT

Mindsets Matter: A New


Framework for Harnessing the
Placebo Effect in Modern Medicine
Sean R. Zion1, Alia J. Crum
Stanford University, Stanford, CA, United States
1
Corresponding author: e-mail address: szion@stanford.edu

Contents
1. Introduction 138
2. The Treatment Effect: Drug Plus Placebo Effects 140
3. Psychological Processes Activate Neurobiological Mechanisms 142
3.1 Implicit Learning 143
3.2 Expectancy 144
3.3 Mindsets 146
4. Social and Contextual Factors Inform Psychological Processes 148
4.1 Developmental and Cultural Factors 149
4.2 The Patient–Provider Relationship—Communication, Warmth, and
Competence 150
4.3 Social Influence and Observational Learning 152
4.4 Treatment Type and Characteristics 153
5. Discussion 155
Acknowledgments 156
References 156

Abstract
The clinical utility of the placebo effect has long hinged on physicians deceptively
administering an objective placebo treatment to their patients. However, the power
of the placebo does not reside in the sham treatment itself; rather, it comes from
the psychosocial forces that surround the patient and the treatment. To this end, we
propose a new framework for understanding and leveraging the placebo effect in clin-
ical care. In outlining this framework, we first present the placebo effect as a neurobi-
ological effect that is evoked by psychological processes. Next, we argue that along with
implicit learning and expectation formation, mindsets are a key psychological process
involved in the placebo effect. Finally, we illustrate the critical role of the social environ-
ment and treatment context in shaping these psychological processes. In doing so, we
offer a guide for how the placebo effect can be understood, harnessed, and leveraged in
the practice of modern medicine.

International Review of Neurobiology, Volume 138 # 2018 Elsevier Inc. 137


ISSN 0074-7742 All rights reserved.
https://doi.org/10.1016/bs.irn.2018.02.002
138 Sean R. Zion and Alia J. Crum

1. INTRODUCTION
Henry Beecher, a World War II army medic, is credited with bringing
about the modern study of the placebo effect. Upon exhausting his supply of
morphine, Beecher continued treating his wounded patients with saline
solution while reassuring them of the pain-relieving power of the infusion.
His observation that patients tended to improve with the sham treatment
and comforting words led to the publication of “The Powerful Placebo,”
which reported on the magnitude of the placebo effect across 15 clinical tri-
als. Beecher’s analysis revealed that over 35% of patients experienced ther-
apeutic benefit from placebo treatments (Beecher, 1955). His finding
intrigued a generation of scientists and laid the groundwork for decades
of subsequent research on the placebo effect.
Since Beecher’s time, the placebo effect has taken on new meaning
depending on the context in which it is studied. In randomized, double-
blind clinical drug trials, new drugs and treatments are compared to a
placebo control. This gold standard for pharmaceutical research and devel-
opment enables researchers to quantify the efficacy of the treatment as it
compares to the effect of the placebo. The ultimate goal of these trials is
to demonstrate the benefit of the active treatment beyond that of the pla-
cebo, and consequently, much of clinical research aims to subtract out or
do away with the placebo effect (Crum, Leibowitz, & Verghese, 2017).
Even when a significant difference between the active treatment and the pla-
cebo is found, any effect of the placebo is later usually forgotten. Despite the
fact that the placebo effect yields clinically significant benefits in clinical trials
for well over half of all medical conditions—including pain, depression,
Parkinson’s disease, anxiety disorders, cardiovascular disorders, and immuno-
logical diseases (de la Fuente-Fernandez & Stoessl, 2002; Goebel, Meykadeh,
Kou, Schedlowski, & Hengge, 2008; Levine, Gordon, Smith, & Fields, 1981;
Petrovic et al., 2005; Pollo, Vighetti, Rainero, & Benedetti, 2003; Shetty,
Friedman, Kieburtz, Marshall, & Oakes, 1999; Walsh, Seidman, Sysko, &
Gould, 2002)—the symbolic effect of randomized placebo-controlled trials
is that placebos are seen either as an adversary that competes with the drug
of interest or as an irrelevant variable to be discounted.
However, a handful of researchers have explored the placebo effect in its
own right. Inspired to understand the strength of and mechanisms behind
Mindsets Matter 139

the placebo effect, psychologists and neurobiologists have designed studies


to investigate how a placebo alone can produce measurable benefit. These
studies consider the placebo as the primary variable of interest, not merely as a
control. Laboratory experiments have demonstrated the ability to evoke pla-
cebo responses through classical conditioning paradigms and through the
manipulation of expectations (Montgomery & Kirsch, 1997). These para-
digms reveal that placebo administration drives changes in both endogenous
opioid and nonopioid neurotransmitter systems and modulates metabolic
activity in many regions of the brain (Amanzio & Benedetti, 1999;
Benedetti, 2008; Levine & Gordon, 1984).
While both clinical trials and direct placebo research have made great
strides in illuminating the power and mechanisms of placebo effects, rela-
tively little research has been devoted to understanding how placebo effects
may be leveraged in clinical practice without the deceptive administration of
an actual placebo treatment. In an effort to make progress in the clinical
applications of the placebo effect, we offer a new framework for understand-
ing the nature and clinical utility of this effect in the practice of medicine.
This framework builds upon the wealth of existing clinical, neurobiological,
and psychological research on the placebo effect and extends it by explaining
how the components underlying placebo effects operate in clinical practice,
without an objective placebo. We argue that the placebo effect is: (1) an
integral component of the overall treatment effect in medicine, (2) a neu-
robiological effect that is evoked by specific psychological processes, which
are shaped by social and environmental factors, and (3) a variable that can be
harnessed, personalized, and maximized in the practice of medicine without
the use of inert placebo pills or sham treatments. Through this conceptual-
ization of the placebo effect, we can see that the placebo effect is neither a
nuisance nor a mystery. It is a real and powerful effect that can be utilized in
the practice of medicine by understanding and leveraging the psychosocial
forces that surround a medical treatment.
In the sections that follow, we review the components of the treatment
effect and explore how the effects of the drug and the placebo can be dis-
entangled. We then describe the psychological processes that drive the neu-
robiological mechanisms that underlie the placebo effect. Finally, we discuss
the social and contextual factors that inform and shape these psychological
processes, offering a roadmap for how they can be harnessed in the practice
of medicine.
140 Sean R. Zion and Alia J. Crum

2. THE TREATMENT EFFECT: DRUG PLUS PLACEBO


EFFECTS
The drug effect and the placebo effect have long been considered sep-
arate and often competing entities, as evidenced by the placebo’s aforemen-
tioned role in randomized control trials. What are these two effects and how
can they be disentangled? The drug effect is the quantifiable change in dis-
ease processes that result from the pharmacological or physical properties of
an active treatment—often a medication. These medications evoke clinical
change by either: (a) simulating or stimulating normal biological processes
that occur in the body or inhibiting processes that contribute to disease,
or (b) blocking critical processes in microorganisms inhabiting the body.
But these mechanisms are responsible for only part of a treatment’s total
effect. Placebo effects also occur as an inherent part of all active medical
treatments, and the effect of the drug and the effect of the placebo work
together to produce the total treatment effect (Fig. 1). From the patient’s
perspective, the components that contribute to the treatment effect are
not particularly relevant—improvement from the drug or improvement
from the psychosocial factors that drive the placebo effect is improvement
nonetheless. However, for the health care practitioner, it is incredibly
important to understand the components that drive the placebo effect and
how they might interact with the drug effect.
The placebo effect can be considered in terms of its biological, psycholog-
ical, and social/contextual components (Table 1). Driven by neurobiological

Fig. 1 The drug effect and the placebo effect contribute to the total effect of treatment.
These components drive the total improvement a patient experiences from a medical
treatment.
Mindsets Matter 141

Table 1 The Components of the Placebo Effect: Neurobiological Mechanisms (The


Body’s Healing Properties and Neurophysiology), Psychological Processes (Implicit
Learning, Expectations, and Mindsets), and Social/Contextual Factors (Social
Environment and Treatment Context)
Components of the Placebo Effect
Biological mechanisms
Body’s healing properties Biological properties of the body that facilitate
healing, including homeostatic mechanisms,
immune, and inflammatory responses. These
contribute to the natural history of a disease, but can
also be targets of placebo effects
Neurophysiology Dopamine, endogenous opioids, and
endocannabinoids are three of the major
neurotransmitter systems implicated in moderating
the placebo effect
Psychological processes
Implicit learning The nonconscious acquisition of knowledge.
Classical conditioning, a form of implicit learning, is
implicated in certain instances of the placebo effect
Expectations A belief about the future based on a prediction of
what is most likely to happen. Expectations underlie
certain instances of the placebo effect and drive
neurobiological mechanisms
Mindsets A lens or frame of mind that orients an individual to a
particular set of beliefs, associations, and expectations,
and functions to guide attentional and motivational
processes
Social and contextual factors
Development and culture Our caregivers and social environment influence the
psychological processes that underlie the placebo
effect. These processes are continuously shaped
throughout life by the ideas, institutions, and
interactions that constitute the culture in which we live
Patient-provider The patient–provider relationship shapes the mindsets
relationship a patient holds about health, illness, and treatments, and
affects the quality of care a patient receives. This
relationship is influenced by the warmth and
competence of the provider and is further shaped by
characteristics like empathy and trust
Continued
142 Sean R. Zion and Alia J. Crum

Table 1 The Components of the Placebo Effect: Neurobiological Mechanisms (The


Body’s Healing Properties and Neurophysiology), Psychological Processes (Implicit
Learning, Expectations, and Mindsets), and Social/Contextual Factors (Social
Environment and Treatment Context)—cont’d
Components of the Placebo Effect
Observational learning and Learning through direct observation of others
social influence undergoing treatment (i.e., other patients) as well as
interactions with individuals who yield influence
over the patient (i.e., physicians and nurses) both may
powerfully drive placebo effects
Treatment characteristics The specific characteristics of the treatment that is
provided to the patient. This includes factors like the
shape, color, and branding of the treatment, the
method of administration, and the physical
environment in which the treatment is administered

mechanisms, the placebo effect recruits the involvement of disease-specific


biological and neurotransmitter systems, such as components of the immune
system and the endogenous opioid system. These biological mechanisms are
evoked and modulated by conscious and nonconscious psychological pro-
cesses, including implicit learning, expectations, and mindsets. Psychological
processes, in turn, are shaped by the social environment and treatment con-
text. As such, a social or environmental factor—like a knowledgeable and
understanding physician who the patient trusts—can shape a patient’s
mindset about a disease or treatment, which can in turn evoke a biological
change and subsequent healing response. In the remaining sections, we
unpack these biological, psychological, and social elements underlying
placebo effects that form the foundation of the treatment effect for all drugs
and therapies.

3. PSYCHOLOGICAL PROCESSES ACTIVATE


NEUROBIOLOGICAL MECHANISMS
Placebo effects are marked by neurobiological underpinnings
(Wager & Atlas, 2015), which are activated by psychological processes.
Two such processes have received the majority of research in this domain:
nonconscious implicit learning, such as classical conditioning, and conscious
expectations (Finniss, Kaptchuk, Miller, & Benedetti, 2010; Price et al.,
1999). These mechanisms are neither mutually exclusive nor the only
two mechanisms through which the placebo effect is thought to operate
Mindsets Matter 143

(Stewart-Williams & Podd, 2004). Other mechanisms, like our mindsets,


also play an important role in the placebo effect, but have received less atten-
tion. In the next sections, we review the existing literature on the role of
implicit learning, expectations, and mindsets as they relate to the placebo
effect in patients undergoing medical treatment. In particular, we review
how these psychological elements trigger the neurobiological processes that
lead to the measurable changes we refer to collectively as the placebo effect.

3.1 Implicit Learning


Implicit learning is a process by which information is learned outside of con-
scious awareness (Frensch & R€ unger, 2003). It is a process of detecting asso-
ciations within an environment and storing this information in the form of
abstract representations (Seger, 1994). Classical conditioning, a form of
implicit learning, underlies certain instances of the placebo effect. Early
evidence for the role of implicit learning in the placebo effect came from
animal studies (Ader & Cohen, 1982, 1993), versions of which were later
replicated in humans (Goebel et al., 2002). Many of these studies repeatedly
paired a neutral stimulus—the placebic vehicle (i.e., syringe or capsule)—
with an unconditioned stimulus (i.e., the drug inside the syringe or capsule).
Other experimental techniques in humans have also been used to tease apart
the mechanism of conditioned placebo responses. For example, the use of
“surreptitious reduction” paradigms in which a placebo treatment is paired
with the hidden reduction of a painful stimulus also provides evidence for
conditioned responses in studies of placebo analgesia (Voudouris, Peck, &
Coleman, 1989, 1990).
Through similar processes, symbols and rituals within the medical
context become associated with healing. Being directed to the exam room,
having temperature, blood pressure, and heart rate measurements taken, and
waiting patiently for the physician may all serve as situational cues that
become implicitly associated with healing. Over time, these contextual cues
are repeatedly paired with active medical treatments. Eventually, exposure
to these cues alone may evoke conditioned responses in patients. Outside
of the doctor’s office, positive or negative experiences with active treatments
may lead to associative links between treatment characteristics and out-
comes. A child given bright pink, bubble-gum flavored liquid penicillin
each time he or she has a bacterial infection will come to associate the per-
ceptual characteristics of this medication with the subsequent healing
response. Indeed, multiple sclerosis patients who received cyclophosphamide
144 Sean R. Zion and Alia J. Crum

(an immune suppressant) paired with a flavored syrup later displayed drug-
consistent immune responses to the flavored syrup alone (Giang et al., 1996).
How does the nonconscious formation of associative links between
healing symbols and treatment outcomes evoke quantifiable biological
changes in the patient? Implicit learning recruits disease-related processes
in the body to change objective biological markers. This has been demon-
strated in studies of conditioned immune and allergic responses in both
humans and animals. For example, conditioning rats with cyclosporine A,
an immunosuppressive drug, resulted in sympathetic nervous system-mediated
immune suppression even when the drug was absent (Exton et al., 2002). In
humans, pairing the same immunosuppressant drug, cyclosporine A, with a
flavored beverage reduced lymphocyte cell count, cytokine release, and
expression of mRNA when the flavored beverage was later given on its
own (Goebel et al., 2002). Side effects of active treatments also appear to
be conditioned alongside the intended treatment effects. In a study by
Benedetti and colleagues, subjects were given a powerful opioid analgesic
medication that was subsequently replaced with a placebo treatment as part
of a conditioning paradigm. Subjects not only experienced the main effects
of the opioid when given the placebo, but they also exhibited respiratory
depression, a common side effect of opioids (Benedetti, Amanzio, Baldi,
Casadio, & Maggi, 1999).
In the practice of medicine, some benefit is derived from years of asso-
ciating positive outcomes with white coats, pills, and exam rooms. While
this may paint a picture of a patient mindlessly linking stimuli and response
(Wickramasekera, 1980), implicit learning processes often induce positive
responses by reinforcing patient expectations (Rescorla, 1988), as most con-
ditioning paradigms in humans inherently manipulate expectations to some
degree (Benedetti, Pollo, et al., 2003; Montgomery & Kirsch, 1997).
Indeed, implicit learning is not required for placebo effects. Thus, while
implicit learning may work directly, it may also operate by influencing
our conscious expectations.

3.2 Expectancy
Expectations are beliefs about the nature and likelihood of future states. The
expectation of a specific outcome can elicit cognitive, emotional, and
behavioral changes that increase the likelihood of that event occurring
(Kirsch, 1985; Montgomery & Kirsch, 1997). Expectations have been
shown to be one mechanism driving many instances of the placebo effect.
Mindsets Matter 145

Studies employing an open/hidden experimental design allow researchers


to disentangle the contribution of expectations from drug effects. In this
paradigm, a physician administers a drug either in full view of the patient
(open condition) or hidden from the patient (hidden condition). Open
administration mimics the conditions of routine medical practice, while
hidden administration removes the external factors that contribute to the
formation of expectations. The difference between these two conditions
reflects the impact of the patients’ psychological processes, like expectations,
that can elicit real and quantifiable effects. Critically, this paradigm allows
the role of expectations to be quantified without actually administering a
placebo treatment. Studies employing open/hidden designs have found
that medical treatments given covertly are less effective than those given
openly, highlighting the contribution of expectations to the efficacy of
treatments (Colloca, Lopiano, Lanotte, & Benedetti, 2004). This has been
observed in numerous clinical conditions, including pain, anxiety, and
Parkinson’s disease (Benedetti, Maggi, et al., 2003; Levine & Gordon,
1984; Pollo et al., 2002).
Placebo analgesia has also been used as a paradigm to demonstrate the
effect of positive or negative expectations on treatment efficacy (Price,
Finniss, & Benedetti, 2008; Price et al., 1999). Compared to a
no-expectation condition, patients who expected the potent analgesic
remifentanil to work well experienced twice the analgesic effect, while those
who held negative expectations experienced no analgesia (Bingel et al.,
2011). These subjective effects corresponded with significant changes in
the endogenous pain modulatory system. Imaging data from various clinical
populations further demonstrate the mechanisms by which expectations
evoke neurobiological responses in patients. In a study of patients with irri-
table bowel syndrome, verbal suggestions of pain relief produced clinically
significant placebo effects. This placebo analgesia corresponded with
reduced activity in the thalamus, somatosensory cortices, insula, and anterior
cingulate and increased activity was noted in the rostral portion of the ante-
rior cingulate, the amygdala, and the periaqueductal gray (Price et al., 2008).
Furthermore, in a revealing study employing an open/hidden paradigm to
quantify the magnitude of expectations on postsurgical dental pain, injecting
saline in full view of the patient reduced pain at a magnitude equal to 6–8 mg
of morphine (Levine & Gordon, 1984; Levine, Gordon, Bornstein, &
Fields, 1979). In other words, when patients were not aware they were
receiving treatment, and thus did not expect to receive benefit, it was as
if they had been given 6–8 mg less morphine than they actually had.
146 Sean R. Zion and Alia J. Crum

The effect of expectation on pain is powerful, and it is therefore critical


for physicians to be aware of how they are inducing and shaping patient
expectations. Physicians may even have the ability to shape expectations
and evoke placebo effects in patients who have formed maladaptive or
harmful associative links between certain treatments and poor outcomes.
For example, a 2003 study demonstrated that manipulating expectations
was effective in overriding negative responses to pharmacological
preconditioning in a placebo analgesia paradigm (Benedetti, Pollo, et al.,
2003). However, in the clinical context, expectations are not always
induced intentionally or explicitly. They are shaped by patients’ mindsets,
the social environment, and the treatment context in which a medical
intervention occurs.

3.3 Mindsets
Mindsets are lenses or frames of mind that orient individuals to particular
sets of associations and expectations (Crum, Salovey, & Achor, 2013).
Mindsets help individuals make sense of complex information by offering
them simple schematics about themselves and objects in their world. For
patients, mindsets provide a scaffolding for understanding the broad
nature of illnesses and treatments. While expectations and mindsets are
intimately connected, they are not the same thing. Expectations are spe-
cific beliefs about future events. Mindsets are a more general psychological
construal that orient an individual to a number of mindset-consistent
expectations. For example, the mindset that “cancer is a catastrophe”
may be associated with a number of different expectations such as “the
treatment will be painful and keep me from the things I enjoy” or “I will
not be able to cope with this” that are beyond the more specific expec-
tations of believing a treatment will or will not work. Thus, understanding
broader mindsets is also important for understanding the impact of ill-
nesses and treatments.
Mindsets guide patients’ attentional and motivational processes and affect
both subjective and objective measures of health and well-being (Crum &
Zuckerman, 2007). This has been documented in studies of stress, diet, and
exercise, in which mindsets were found to affect both psychological states
and markers of physical health, including blood pressure, weight loss, cor-
tisol response, and hormone secretion (Crum, Corbin, Brownell, & Salovey,
2011; Crum & Langer, 2007; Crum et al., 2013). Research is beginning to
shed light on mindsets about health and disease and their subsequent impact
on patients, providers, and the health care system (Crum et al., 2017).
Mindsets Matter 147

Mindsets can be intentionally and adaptively changed through targeted


interventions. These interventions bridge the gap between traditional
psychosocial interventions that primarily focus on improving subjective
measures of well-being and medical interventions that are often evaluated
exclusively in terms of their impact on physiological measures of health.
For example, when exposed to information about the positive aspects of
stress—that it can enhance immune function and boost cognitive
performance—individuals with high stress finance jobs adopted a “stress is
enhancing” mindset that shaped subsequent work performance (Crum
et al., 2013). Similarly, hotel employees who were taught that their work
provides a sufficient amount of daily physical activity, showed improvement
on vital measures of health, without evidence of a corresponding behavior
change (Crum & Langer, 2007). This research has also demonstrated that
effective interventions can be short, simple, and inexpensive. So while
patients may come to health care with their own preexisting mindsets,
the malleability of mindsets suggests that physicians can intentionally shape
their patients’ mindsets. Helping a patient develop the mindset that their
disease is manageable (as opposed to a catastrophe), for instance, may impact
patient expectations about the course of their illness, the nature and occur-
rence of symptoms, and the efficacy of treatments. Rather than simply
shaping expectations (e.g., this drug will work), physicians may be able to
help their patients form more adaptive mindsets that elicit multiple down-
stream effects.
How do mindsets and expectations relate to one another in the clinical
context? A patient in pain, for instance, may have the specific expectation
that a treatment will relieve their discomfort. However, this expectation
may hinge on the broader mindset that their illness is manageable. These
mindsets and the expectations they influence activate distinct brain regions
associated with pain, anxiety, and reward (Benedetti, Carlino, & Pollo,
2011; Bingel et al., 2011; Zubieta & Stohler, 2009). They also affect the
function of the peripheral nervous system and its downstream target organs
and modulate the activity of the immune and endocrine systems (Crum
et al., 2011; Pollo et al., 2003). While specific expectations facilitate placebo
effects in experimental paradigms, mindsets may be particularly relevant in
the practice of medicine, where individual expectations do not exist in
isolation from one another.
Patients often enter the medical context with preexisting mindsets about
health, disease, and treatments. When a physician shares information about
disease and treatment with a patient, it is interpreted through the lens of
the patient’s mindsets, influencing his or her subsequent expectations.
148 Sean R. Zion and Alia J. Crum

The interactions that occur in the clinical context and the experience a
patient has with his or her illness and treatment then shape existing mindsets,
reinforcing or altering them. For example, a patient who has the mindset
that their body is capable may preferentially attend to signals that their body
is handling an illness well (Zion, Dweck, & Crum, 2018). They may expect
their body to be able to manage an illness and the side effects of treatment.
Critically, these expectations can often be self-fulfilling and an understand-
ing and compassionate physician can help reinforce these adaptive mindsets
(Howe, Goyer, & Crum, 2017).

4. SOCIAL AND CONTEXTUAL FACTORS INFORM


PSYCHOLOGICAL PROCESSES
In Sections 2 and 3, the patient’s internal psychological characteristics
that contribute the placebo effect were discussed. Of course, these processes
like implicit learning, conscious expectations, and mindsets do not exist in a
vacuum; they are critically informed by the environment. Here, we break
down the components of the social context and the treatment context that
influence patient mindsets and contribute to the placebo effect in the prac-
tice of medicine (Fig. 2). First, we review some of the developmental and
cultural factors that shape psychological processes outside the doctor’s office.
Next, we move into the social and contextual factors that influence psycho-
logical processes within the clinical context, including the patient–provider

Fig. 2 The relationship between the components of the placebo effect. Social and con-
textual factors inform psychological processes, which in turn activate biological
mechanisms.
Mindsets Matter 149

relationship and social and observational learning. Finally, we review how


the components of the treatment context—the characteristics of treatments
and the physical environment—affect our psychological processes.

4.1 Developmental and Cultural Factors


The psychological processes that drive placebo effects may be set into
motion long before a patient sets foot into a doctor’s office. As children,
our mindsets are shaped, in part, by our caregivers and our social environ-
ment (Gunderson et al., 2013; Mueller & Dweck, 1998). Mindsets can also
be shaped less explicitly during these sensitive developmental periods
through social influence and modeling (Bandura, 1977). Mindsets about
health and illness may also develop early on from experiences with illness,
visits to the pediatrician, and from observing family members and peers.
As adults, these health mindsets are continually shaped through our interac-
tions with the health care system and our positive and negative experiences
with disease and treatment.
With age, our experiences shape our mindsets within cultural frame-
works of norms and customs. Our mindsets are influenced by the culture
in which we were raised, our social networks, religious customs, and the
media (Markus & Kitayama, 2010). Culture, for instance, influences how
pain is experienced. Individuals of Italian ancestry may focus on the imme-
diacy of the pain and how it affects their current situation. American Jews
and Protestants, conversely, tend to be more future oriented when
experiencing pain, attending to the potential long-term implications of
the experience (Zborowski, 1952). When managing one’s health, individ-
uals from western cultures in which individual agency and responsibility
are often highly valued favor health promotion over illness prevention.
Patients from East Asian cultures tend to take the opposite approach, favor-
ing prevention over promotion and endorsing motivation for avoiding
negative outcomes (Elliot, Chirkov, Kim, & Sheldon, 2001; Lockwood,
Marshall, & Sadler, 2005).
The information we encounter can also have a particularly potent impact
on our mindsets. For instance, the highly publicized claim citing a link
between the MMR vaccination and autism—a link that has been thoroughly
discredited by every major scientific organization—may have affected some
patients’ mindsets about the nature of vaccines (Godlee, Smith, &
Marcovitch, 2011). Indeed, analyses years after the incident found that par-
ents struggled to understand the true nature of the controversy or know
150 Sean R. Zion and Alia J. Crum

which sources of information to trust (Hilton, Petticrew, & Hunt, 2007).


This trust is important. We place our trust in figures of authority like phy-
sicians and base this trust on their degree of competence, compassion, reli-
ability, and how they communicate information (Pearson & Raeke, 2000).
We assign value to their claims, allowing these figures to shape mindsets in
important ways—for better or for worse.

4.2 The Patient–Provider Relationship—Communication,


Warmth, and Competence
The relationship between patient and provider is a critical factor in the qual-
ity of care a patient receives, but can also influence the beliefs, expectations,
and mindsets patients have about health and disease. The patient–provider
relationship shapes the way important medical information is communicated
and this influences the mindsets a patient holds about health, illness, and
treatments. The patient–provider relationship can also affect physiological
health outcomes, both by motivating behavior and through its impact on
the patient’s internal psychological processes. The patient–provider relation-
ship shapes the patient’s internal psychological processes by both direct
communication and the nonverbal cues that convey competence and
warmth.
How information is framed and communicated can be a particularly
strong influence on patients’ mindsets. Imagine an emergency room physi-
cian meets with an incoming trauma patient. Telling the patient, “I am
going to administer a dose of morphine, a safe but powerful pain killer that
will alleviate your pain” activates a series of related beliefs and expectations
that enhance the subjective and objective efficacy of that treatment. These
verbal suggestions shift attention and motivation and affect brain regions
associated with pain relief and reward (Benedetti, Amanzio, Vighetti, &
Asteggiano, 2006). If the same doctor were to instead tell their patient that
the morphine they were giving them was an addictive opioid that could
cause severe side effects like respiratory depression, a very different network
of beliefs would be activated (Kast & Loesch, 1961). Furthermore, positive
interactions in which a diagnosis is clearly made and agreed upon by both
the patient and the practitioner can speed recovery from illness (Bass
et al., 1986). This effect also occurs in the opposite direction—patients of
physicians who communicate poorly have a 19% higher risk of not adher-
ing to medical advice and treatment regimens (Haskard-Zolnierek &
DiMatteo, 2009).
Mindsets Matter 151

It is not just the way treatments are described that can influence patients’
mindsets. When doctors intentionally or inadvertently assign meaning to
conditions or symptoms, it can shape how the patient experiences them.
Cancer pain, for example, is often perceived as more unpleasant than post-
operative pain. While cancer pain carries with it associations of sickness and
death, postsurgical pain is often associated with a recovery processes (Ferrell,
Dean, Grant, & Coluzzi, 1995; Smith, Gracely, & Safer, 1998). By assigning
positive or negative meaning to pain, medical providers are activating
preexisting mindsets. This can influence pain tolerance and modulate
endogenous opioid and cannabinoid systems in the brain (Zubieta &
Stohler, 2009).
Although there is never one correct way to communicate with a patient
or an ideal model of the patient–provider relationship, certain characteristics
appear to be universally important. Indeed, decades of social psychological
research suggest that two qualities are of paramount importance: warmth
and competence. When a patient meets a physician, he or she rapidly assesses
the benevolence of the physician’s intentions (warmth) and their ability to
carry out these intentions (competence) (Fiske, Cuddy, & Glick, 2007).
Warmth denotes a physician’s understanding of the patient as a whole
person, with a life, values, and goals outside of the health care context, while
competence denotes a physician’s understanding of medicine (i.e., the dis-
ease, prognosis, and treatment). Patient assessments of physician warmth and
competence shape patient expectations about treatment, impact mindsets
about illness, and modulate the magnitude of the placebo effect. In a recent
study, an allergic reaction was induced in participants via a histamine skin
prick. A placebo cream was administered with either positive (i.e., this
cream will reduce your symptoms) or negative (i.e., this cream will exacer-
bate your symptoms) expectations under different conditions of provider
warmth and competence. Expectations had a larger impact on the efficacy
of the placebo cream when it was administered by a warm and competent
provider and negated the effects when administered by a cold and incom-
petent provider (Howe et al., 2017). The social context in which the treat-
ment was administered—seen here as the interaction with a provider who
varied in warmth and competence—moderated the impact of patients’
expectations on their allergic response.
The strength and quality of the patient–provider relationship is further
shaped by empathy and trust. Physicians signal their warmth through their
empathy, or ability to understand a patient’s unique situation. Empathy is
expressed explicitly through verbal information and implicitly through
152 Sean R. Zion and Alia J. Crum

nonverbal cues like head and body position (Harrigan & Rosenthal, 1983).
Displays of warmth and competence not only foster trusting patient–
provider relationships, but they also help patients engage in adaptive psycho-
logical processes. For instance, physician empathy is significantly associated
with reductions in patient anxiety and distress in addition to better clinical
outcomes (Derksen, Bensing, & Lagro-Janssen, 2013). In a large retrospec-
tive study of over 20,000 diabetic patients, the patients of more empathetic
physicians had significantly fewer metabolic complications (Del Canale
et al., 2012). Practitioner characteristics such as empathy also affect biolog-
ical markers of disease. In another study, patients who sought care for
symptoms of the common cold were randomly assigned to either a standard
interaction with a physician or an enhanced, empathetic interaction. Patients
in the enhanced condition rated their physicians as more empathetic,
reported lower severity of cold symptoms, and had a greater change in
interleukin-8 (IL-8) and neutrophil counts 48 h after the interaction
(Rakel et al., 2011).

4.3 Social Influence and Observational Learning


Medical treatments occur within a social environment that directly shapes
their efficacy. Indeed, observational learning and social influence have long
been suggested as potential mechanisms underlying certain placebo effects
(Bootzin & Caspi, 2002). A patient who observes the behavior of another
patient may modify their behaviors to more closely match those of the
subject being observed (Zentall & Galef, 2013). Behavior modification,
however, is not always needed to mediate the effect of observational learning
on health outcomes. In an illuminating study, Colloca and Benedetti (2009)
demonstrated that placebo effects can be experimentally induced through
observational social learning (Colloca & Benedetti, 2009). In this study,
participants who observed others undergoing an analgesic procedure expe-
rienced substantial placebo responses to the same paradigm. The placebo
effect induced via social observation was comparable to those induced by
conditioning and greater than those induced by verbal suggestion. The
patient’s degree of empathy was positively correlated with their placebo
response, a finding that has implications for future research. The influence
of social observation has important implications for certain integrative
medical treatments and the design of novel interventions. For example,
support groups or other forms of social interaction between patients may
serve to encourage patients currently undergoing treatment, recruit some
Mindsets Matter 153

of these learning mechanisms to improve treatment efficacy, and comple-


ment the verbal and nonverbal expectations induced by a health care
provider.
In addition to observational learning, placebo effects can be modulated
by explicit social influence. After consuming bottled water that was labeled
as caffeinated, participants exhibited increased alertness, increased motor
function, and decreased cognitive interference. These effects were largest
for subjects who heard a confederate report positive effects from the faux
caffeinated water, suggesting an important role of social influence. Further-
more, these socially influenced subjects were more likely to purchase the
product and endorse its effects to others (Crum, Phillips, Goyer, Akinola,
& Higgins, 2016). These findings suggest that patients may be influenced
by others who express confidence in specific treatments. While this social
influence may come directly from other patients, it may also come from
the media and advertising, which tend to portray new and innovative treat-
ments with compelling success stories.

4.4 Treatment Type and Characteristics


The physical environment in which the treatment takes place and the
specific characteristics of the treatment itself can activate certain beliefs,
expectations, and mindsets, thereby influencing treatment outcomes. Many
patients, for instance, exhibit a substantial but transient rise in blood pressure
when it is measured by a physician in a medical setting. This so-called white
coat syndrome is thought to result from a physiological stress response
evoked by the symbolic status and authority that is represented by the
physician’s traditional white coat (Manios et al., 2008). Indeed, studies have
demonstrated that both representations of social influence and authority can
shape a patient’s psychological processes and subsequently affect clinical
outcomes (Den Hond, Celis, Vandenhoven, O’brien, & Staessen, 2003).
However, if this blood pressure reading is used as the basis for a diagnosis
of hypertension, it may lead to over medicating of patients who are simply
exhibiting a physiological response to the meaning of an environmental cue.
Perceptual characteristics of the treatment itself have also been found to
play a role in shaping both psychological processes and treatment outcomes.
Seemingly inconsequential features, such as the color of a medication can
impact perceptions of medication quality and consequently affect the
actual efficacy of that treatment. A 1996 study indicated that patients
relate the color of a drug to its underlying mechanism and efficacy
154 Sean R. Zion and Alia J. Crum

(de Craen, Roos, Leonard de Vries, & Kleijnen, 1996). Shape and form also
play a role according to a study in which patients perceived capsules to be
stronger and more effective than tablets (Buckalew & Coffield, 1982).
Cost may serve as a mediator between the social valuation of an object
and the impact that object has on the individual. Numerous studies have
found that beliefs about the characteristics of consumer goods—unrelated
to their objective characteristics—shape how they are perceived (Lee,
Frederick, & Ariely, 2006). Knowing the price of a bottle of wine, for
instance, influences how pleasant that wine is perceived to be and affects
blood oxygen levels in the medial orbitofrontal cortex, a region of the brain
that is involved in expectation and reward (Kringelbach, 2005; Plassmann
et al., 2008). Price has also been found to moderate the efficacy of treatments
in clinical populations. In a double-blind study, patients with Parkinson’s
disease were randomized to receive an injection of saline that was described
as either an inexpensive or an expensive “novel injectable dopamine
agonist” (Espay et al., 2015). Patients responded to both placebo treatments,
but those who received the expensive placebo exhibited greater benefit.
If given an expensive treatment first, patients exhibited a twofold increase
in motor function over the cheaper placebo. These changes in motor func-
tion were associated with corresponding changes in activation of the left
putamen, a major target for dopaminergic projections that govern motor
activation in Parkinson’s disease.
Similar effects have been found in patients’ strong preferences for brand
name rather than generic drugs. Although generic drugs and their brand
name counterparts contain the same type and dose of medication, patients
perceive generic drugs to be less effective and experience more side effects
when taking them. Generic drugs are also viewed as less trustworthy, less
powerful, and many patients do not feel they are appropriate for serious
medical conditions (Figueiras et al., 2010; Himmel et al., 2005). In a related
study, university students were given placebos and told they would be
taking a new beta-blocker (an antihypertensive medication) to reduce per-
formance anxiety. Subjects were randomized to remain taking the original
“medication” or to switch to either a different brand or a generic condition.
Those who remained on the same placebo treatment exhibited a greater
reduction in blood pressure and anxiety compared to those who changed
treatments. The switch to a generic beta-blocker yielded the lowest efficacy
and the greatest number of adverse events (Faasse, Cundy, Gamble, &
Petrie, 2013).
Mindsets Matter 155

5. DISCUSSION
In this chapter, we have argued that the power of the placebo effect is
not separate from but a critical component of medical treatment. In other
words, the total effect of any treatment is the combined effect of the phar-
maceutical agent and the psychosocial components that make up the placebo
effect. These components include the psychological processes and social/
contextual factors that drive neurobiological changes and influence subjec-
tive and objective treatment outcomes. They can powerfully shape the
impact of an active treatment and should not be discounted in the practice
of medicine where they can be harnessed to improve patient care.
The power of the placebo to boost active treatments is not novel to many
clinicians who witness its effects in their own patients on a daily basis.
However, for decades, the notion of the placebo effect was synonymous
with deceiving patients by prescribing an inert treatment, a practice that
is at odds with the core principles of the profession. So how can the placebo
effect be ethically harnessed in the practice of medicine? First, we encourage
a wider dissemination of knowledge about the nature of the placebo effect as
a psychological process with disease-specific neurobiological effects that are
shaped by the social environment and treatment context. This process then
can be harnessed to improve patient care and treatment outcomes in a
relatively simple and cost-efficient way.
Second, we suggest being aware of each patient’s individual psycholog-
ical characteristics and tendencies, with a specific focus on their mindsets and
expectations. How does each patient think about themselves and the world?
Recognizing patients who may hold maladaptive mindsets and observing
how these mindsets shape their expectations and subsequent health, disease,
and treatment is one way to harness the power of the placebo effect in the
clinical encounter. Taking an active role in understanding how and why
patients have the mindsets they have about health and healing could allow
physicians to nondeceptively leverage the same forces that underlie placebo
effects in the clinical encounter.
Finally, we encourage physicians to recognize that how they interact
with their patients shapes the social environment and treatment context,
which in turn influences patient health outcomes. Does the patient trust
that the provider has his or her best intentions in mind? Does the patient
feel like he or she is understood as a whole person, not just as a body with
156 Sean R. Zion and Alia J. Crum

a disease? Does the provider exude characteristics of both warmth and


competence? These variables are within the provider’s control and can
powerfully shape the ability to optimize treatment efficacy.
In understanding how the social environment and treatment context
shape psychological processes, thereby affecting treatment outcomes, phy-
sicians today can harness the same power that Henry Beecher harnessed over
50 years ago—the power of the placebo phenomenon. This helps us move
from a world in which the placebo effect is associated with deceptively
administered sham treatments, to a world in which the placebo effect is
recognized as the manifestation of the powerful social and psychological
forces that scaffold all of medicine.

ACKNOWLEDGMENTS
We wish to acknowledge and thank the Stanford Mind & Body Lab, Kari Leibowitz, and
Isaac Handley-Miner for their feedback and comments on the manuscript.

REFERENCES
Ader, R., & Cohen, N. (1982). Behaviorally conditioned immunosuppression and murine
systemic lupus erythematosus. Science, 215(4539), 1534–1536.
Ader, R., & Cohen, N. (1993). Psychoneuroimmunology: Conditioning and stress. Annual
Review of Psychology, 44, 53–85.
Amanzio, M., & Benedetti, F. (1999). Neuropharmacological dissection of placebo analgesia:
Expectation-activated opioid systems versus conditioning-activated specific subsystems.
The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 19(1), 484–494.
Bandura, A. (1977). Social learning theory. Englewood Cliffs, NJ: Prentice-Hall.
Bass, M. J., Buskc, C., Turner, L., Dickie, G., Pratt, G., & R.H. (1986). The physician’s
actions and the otucome of illnes in family practice. The Journal of Family Practice, 23,
43–47.
Beecher, H. K. (1955). The powerful placebo. JAMA, 159(17), 1602–1606.
Benedetti, F. (2008). Mechanisms of placebo and placebo-related effects across diseases and
treatments. Annual Review of Pharmacology and Toxicology, 48, 33–60.
Benedetti, F., Amanzio, M., Baldi, S., Casadio, C., & Maggi, G. (1999). Inducing placebo
respiratory depressant responses in humans via opioid receptors. European Journal of
Neuroscience, 11(2), 625–631.
Benedetti, F., Amanzio, M., Vighetti, S., & Asteggiano, G. (2006). The biochemical and
neuroendocrine bases of the hyperalgesic nocebo effect. The Journal of Neuroscience,
26(46), 12014–12022.
Benedetti, F., Carlino, E., & Pollo, A. (2011). How placebos change the patient’s brain.
Neuropsychopharmacology, 36(1), 339–354.
Benedetti, F., Maggi, G., Lopiano, L., Lanotte, M., Rainero, I., Vighetti, S., et al. (2003).
Open versus hidden medical treatments: The patient’s knowledge about a therapy affects
the therapy outcome. Prevention & Treatment, 6(1).
Benedetti, F., Pollo, A., Lopiano, L., Lanotte, M., Vighetti, S., & Rainero, I. (2003).
Conscious expectation and unconscious conditioning in analgesia, motor, and hormonal
placebo/nocebo responses. The Journal of Neuroscience: The Official Journal of the Society for
Neuroscience, 23(10), 4315–4323.
Mindsets Matter 157

Bingel, U., Wanigasekera, V., Wiech, K., Ni Mhuircheartaigh, R., Lee, M. C., Ploner, M.,
et al. (2011). The effect of treatment expectation on drug efficacy: Imaging the analgesic
benefit of the opioid remifentanil. Science Translational Medicine, 3(70), 70ra14.
Bootzin, R. R., & Caspi, O. (2002). Explanatory mechanisms for placebo effects: Cognition,
personality and social learning. In H. A. Guess, A. Kleinman, J. W. Kusek, & L. W. Engel
(Eds.), The science of the placebo: Toward an interdisciplinary research agenda (pp. 108–132).
London: BMJ Books.
Buckalew, L. W., & Coffield, K. E. (1982). An investigation of drug expectancy as a function
of capsule color and size and preparation form. Journal of Clinical Psychopharmacology, 2(4),
245–248.
Colloca, L., & Benedetti, F. (2009). Placebo analgesia induced by social observational learn-
ing. Pain, 144(1), 28–34.
Colloca, L., Lopiano, L., Lanotte, M., & Benedetti, F. (2004). Overt versus covert treatment
for pain, anxiety, and Parkinson’s disease. The Lancet. Neurology, 3(11), 679–684.
Crum, A. J., Corbin, W. R., Brownell, K. D., & Salovey, P. (2011). Mind over milkshakes:
Mindsets, not just nutrients, determine ghrelin response. Health Psychology, 30(4),
424–429.
Crum, A. J., & Langer, E. J. (2007). Mind-set matters exercise and the placebo effect.
Psychological Science, 18(2), 165–171.
Crum, A. J., Leibowitz, K. A., & Verghese, A. (2017). Making mindset matter. BMJ (Clinical
Research Ed.), 674, j674.
Crum, A. J., Phillips, D. J., Goyer, J. P., Akinola, M., & Higgins, E. T. (2016). Transforming
water: Social influence moderates psychological, physiological, and functional response
to a placebo product. PLoS One, 11(11), 1–18.
Crum, A. J., Salovey, P., & Achor, S. (2013). Rethinking stress: The role of mindsets in
determining the stress response. Journal of Personality and Social Psychology, 104(4),
716–733.
Crum, A., & Zuckerman, B. (2007). Changing mindsets to enhance treatment effectiveness.
JAMA, 317(20), 2063–2064.
de Craen, A. J., Roos, P. J., Leonard de Vries, A., & Kleijnen, J. (1996). Effect of colour of
drugs: Systematic review of perceived effect of drugs and of their effectiveness. BMJ
(Clinical Research Ed.), 313(7072), 1624–1626.
de la Fuente-Fernandez, R., & Stoessl, A. J. (2002). The placebo effect in Parkinson’s disease.
Trends in Neurosciences, 25(6), 302–306.
Del Canale, S., Louis, D. Z., Maio, V., Wang, X., Rossi, G., Hojat, M., et al. (2012). The
relationship between physician empathy and disease complications. Academic Medicine,
87(9), 1243–1249.
Den Hond, E., Celis, H., Vandenhoven, G., O’brien, E., & Staessen, J. A. (2003). Determi-
nants of white-coat syndrome assessed by ambulatory blood pressure or self-measured
home blood pressure. Blood Pressure Monitoring, 8(1), 37–40.
Derksen, F., Bensing, J., & Lagro-Janssen, A. (2013). Effectiveness of empathy in general
practice: A systematic review. British Journal of General Practice, 63(606), 76–84.
Elliot, A. J., Chirkov, V. I., Kim, Y., & Sheldon, K. M. (2001). A cross-cultural analysis of
avoidance (relative to approach) personal goals. Psychological Science, 12(6), 505–510.
Espay, A. J., Norris, M. M., Eliassen, J. C., Dwivedi, A., Smith, M. S., Banks, C., et al.
(2015). Placebo effect of medication cost in Parkinson disease a randomized double-blind
study. Neurology, 84(8), 794–802.
Exton, M. S., Gierse, C., Meier, B., Mosen, M., Xie, Y., Frede, S., et al. (2002). Behaviorally
conditioned immunosuppression in the rat is regulated via noradrenaline and
β-adrenoceptors. Journal of Neuroimmunology, 131(1–2), 21–30.
Faasse, K., Cundy, T., Gamble, G., & Petrie, K. J. (2013). The effect of an apparent change to
a branded or generic medication on drug effectiveness and side effects. Psychosomatic
Medicine, 75(1), 90–96.
158 Sean R. Zion and Alia J. Crum

Ferrell, B. R., Dean, G. E., Grant, M., & Coluzzi, P. (1995). An institutional commitment to
pain management. Journal of Clinical Oncology, 13(9), 2158–2165.
Figueiras, M. J., Cortes, M. A., Marcelino, D., Weinman, J., Joa, M., & Weinman, J. (2010).
Lay views about medicines: The influence of the illness label for the use of generic versus
brand. Psychology and Health, 25(9), 1121–1128.
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010). Placebo effects: Biological,
clinical and ethical advances. Lancet, 375(9715), 686–695.
Fiske, S. T., Cuddy, A. J. C., & Glick, P. (2007). Universal dimensions of social cognition:
Warmth and competence. Trends in Cognitive Sciences, 11(2), 77–83.
Frensch, P. A., & R€ unger, D. (2003). Implicit learning. Current Directions in Psychological
Science, 12(1), 13–18.
Giang, D. W., Goodman, A. D., Schiffer, R. B., Mattson, D. H., Petrie, M., Cohen, N.,
et al. (1996). Conditioning of cyclophosphamide-induced leukopenia in humans. The
Journal of Neuropsychiatry and Clinical Neurosciences, 8(2), 194–201.
Godlee, F., Smith, J., & Marcovitch, H. (2011). Wakefield’s article linking MMR vaccine
and autism was fraudulent. BMJ (Clinical Research Ed.), 342(7788), c7452.
Goebel, M. U., Meykadeh, N., Kou, W., Schedlowski, M., & Hengge, U. R. (2008). Behav-
ioral conditioning of antihistamine effects in patients with allergic rhinitis. Psychotherapy
and Psychosomatics, 77(4), 227–234.
Goebel, M. U., Trebst, A. E., Steiner, J., Xie, Y. F., Exton, M. S., Frede, S., et al. (2002).
Behavioral conditioning of immunosuppression is possible in humans. Official Publication
of the Federation of American Societies for Experimental Biology, 16(14), 1869–1873.
Gunderson, E. A., Gripshover, S. J., Romero, C., Dweck, C. S., Goldin-Meadow, S., &
Levine, S. C. (2013). Parent praise to 1–3 year-olds predicts children’s motivational
frameworks 5 years later. Child Development, 84(5), 1526–1541.
Harrigan, J. A., & Rosenthal, R. (1983). Physicians’ head and body positions as determinants
of perceived rapport. Journal of Applied Social Psychology, 13(6), 496–509.
Haskard-Zolnierek, K. B., & DiMatteo, M. R. (2009). Physician communication and patient
adherence to treatment: A meta-analysis. Medical Care, 47(8), 826–834.
Hilton, S., Petticrew, M., & Hunt, K. (2007). Parents’ champions vs. vested interests: Who
do parents believe about MMR? A qualitative study. BMC Public Health, 7(1), 42.
Himmel, W., Simmenroth-Nayda, A., Niebling, W., Ledig, T., Jansen, R. D.-D.,
Kochen, M. M., et al. (2005). What do primary care patients think about generic drugs?
International Journal of Clinical Pharmacology and Therapeutics, 43(10), 472–479.
Howe, L. C., Goyer, J. P., & Crum, A. J. (2017). Harnessing the placebo effect: Exploring the
influence of physician characteristics on placebo response. Health Psychology, 36(11),
1074–1082.
Kast, E. C. E., & Loesch, J. (1961). Influence of the doctor-patient relationship on drug
action. The Illinois Medical Journal, 119, 390–393.
Kirsch, I. (1985). Response expectancy as a determinant of experience and behavior.
American Psychologist, 40(11), 1189–1202.
Kringelbach, M. L. (2005). The human orbitofrontal cortex: Linking reward to hedonic
experience. Nature Reviews. Neuroscience, 6(9), 691–702.
Lee, L., Frederick, S., & Ariely, D. (2006). Try it, you’ll like it: The influence of expectation,
consumption, and revelation on preferences for beer. Psychological Science, 17(12),
1054–1058.
Levine, J. D., & Gordon, N. C. (1984). Influence of the method of drug administration on
analgesic response. Nature, 312(5996), 755–756.
Levine, J. D., Gordon, N. C., Bornstein, J. C., & Fields, H. L. (1979). Role of pain in placebo
analgesia. Proceedings of the National Academy of Sciences of the United States of America, 76(7),
3528–3531.
Levine, J. D., Gordon, N. C., Smith, R., & Fields, H. L. (1981). Analgesic responses to
morphine and placebo in individuals with postoperative pain. Pain, 10(3), 379–389.
Mindsets Matter 159

Lockwood, P., Marshall, T. C., & Sadler, P. (2005). Promoting success or preventing failure:
Cultural differences in motivation by positive and negative role models. Personality and
Social Psychology Bulletin, 31(3), 379–392.
Manios, E. D., Koroboki, E. A., Tsivgoulis, G. K., Spengos, K. M., Spiliopoulou, I. K.,
Brodie, F. G., et al. (2008). Factors influencing white-coat effect. American Journal of
Hypertension, 21(2), 153–158.
Markus, H. R., & Kitayama, S. (2010). Cultures and selves. Perspectives on Psychological Science,
5(4), 420–430.
Montgomery, G. H., & Kirsch, I. (1997). Classical conditioning and the placebo effect. Pain,
72(1–2), 107–113.
Mueller, C. M., & Dweck, C. S. (1998). Praise for intelligence can undermine children’s
motivation and performance. Journal of Personality and Social Psychology, 75(1), 33–52.
Pearson, S. D., & Raeke, L. H. (2000). Patients’ trust in physicians: Many theories, few
measures, and little data. Journal of General Internal Medicine, 15(7), 509–513.
Petrovic, P., Dietrich, T., Fransson, P., Andersson, J., Carlsson, K., & Ingvar, M. (2005).
Placebo in emotional processing-induced expectations of anxiety relief activate a gener-
alized modulatory network. Neuron, 46(6), 957–969.
Plassmann, H., O’Doherty, J., Shiv, B., Rangel, A., Doherty, J. O., Shiv, B., et al. (2008).
Marketing actions can modulate neural representations of experienced pleasantness.
Proceedings of the National Academy of Sciences of the United States of America, 105(3),
1050–1054.
Pollo, A., Torre, E., Lopiano, L., Rizzone, M., Lanotte, M., Cavanna, A., et al. (2002).
Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian
patients. Neuroreport, 13(11), 1383–1386.
Pollo, A., Vighetti, S., Rainero, I., & Benedetti, F. (2003). Placebo analgesia and the heart.
Pain, 102, 125–133.
Price, D. D., Finniss, D. G., & Benedetti, F. (2008). A comprehensive review of the placebo
effect: Recent advances and current thought. Annual Review of Psychology, 59,
565–590.
Price, D. D., Milling, L. S., Kirsch, I., Duff, A., Montgomery, G. H., & Nicholls, S. S.
(1999). An analysis of factors that contribute to the magnitude of placebo analgesia in
an experimental paradigm. Pain, 83(2), 147–156.
Rakel, D., Barrett, B., Zhang, Z., Hoeft, T., Chewning, B., Marchand, L., et al. (2011).
Perception of empathy in the therapeutic encounter: Effects on the common cold. Patient
Education and Counseling, 85(3), 390–397.
Rescorla, R. A. (1988). Pavlovian conditioning: It’s not what you think it is. American
Psychologist, 43(3), 151–160.
Seger, C. (1994). Implicit learning. Psychological Bulletin, 115(2), 163–196.
Shetty, N., Friedman, J. H., Kieburtz, K., Marshall, F. J., & Oakes, D. (1999). The placebo
response in Parkinson’s disease. Parkinson Study Group. Clinical Neuropharmacology,
22(4), 207–212.
Smith, W. B., Gracely, R. H., & Safer, M. A. (1998). The meaning of pain: Cancer patients’
rating and recall of pain intensity and affect. Pain, 78(2), 123–129.
Stewart-Williams, S., & Podd, J. (2004). The placebo effect: Dissolving the expectancy versus
conditioning debate. Psychological Bulletin, 130, 324.
Voudouris, N. J., Peck, C. L., & Coleman, G. (1989). Conditioned response models of
placebo phenomena: Further support. Pain, 38(1), 109–116.
Voudouris, N. J., Peck, C. L., & Coleman, G. (1990). The role of conditioning and verbal
expectancy in the placebo response. Pain, 43(1), 121–128.
Wager, T. D., & Atlas, L. Y. (2015). The neuroscience of placebo effects: Connecting
context, learning and health. Nature Reviews. Neuroscience, 16(7), 403–418.
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002). Placebo response in studies of
major depression: Variable, substantial, and growing. JAMA, 287(14), 1840–1847.
160 Sean R. Zion and Alia J. Crum

Wickramasekera, I. (1980). A conditioned response model of the placebo effect: Predictions


from the model. Biofeedback and Self-Regulation, 5(1), 5–18.
Zborowski, M. (1952). Cultural components in responses to pain. Journal of Social Issues, 8(4),
16–30.
Zentall, T. R., & Galef, B. G., Jr. (2013). Social learning: Psychological and biological perspectives.
Psychology Press.
Zion, S. R., Dweck, C. S., & Crum, A. J. (2018). In sickness and in health: Validation of a
health mindset scale in healthy and chronically ill populations. In Presented at the Society for
Personality and Social Psychology, Atlanta, GA.
Zubieta, J. K., & Stohler, C. S. (2009). Neurobiological mechanisms of placebo responses.
Annals of the New York Academy of Sciences, 1156(734), 198–210.

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy